<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231815</url>
  </required_header>
  <id_info>
    <org_study_id>2008-007746-58</org_study_id>
    <nct_id>NCT01231815</nct_id>
  </id_info>
  <brief_title>Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner</brief_title>
  <acronym>RECOPE</acronym>
  <official_title>Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplantation is the ultimate therapeutic option in patients with end-stage heart&#xD;
      failure. Since advances in the treatment of acute rejection has increased early transplant&#xD;
      survival, cardiac allograft vasculopathy (CAV) is the main factor limiting long-term&#xD;
      survival. The prevalence of angiographically proven CAV is high, documented in 40-50% of&#xD;
      transplant recipients 5 years after transplantation. Therefore, annual coronary angiography&#xD;
      remains widely used to monitor transplanted patients, although pathologic studies and&#xD;
      intravascular ultrasonography have demonstrated that coronary angiography underestimates the&#xD;
      severity of CAV. Perfusion SPECT may underestimate allograft vasculopathy in case of diffuse&#xD;
      coronary lesions. In this setting, the assessment of coronary reserve by means of Positron&#xD;
      Emission Tomography (PET) and perfusion cardiac magnetic resonance imaging (CMR) have not&#xD;
      been investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study. The aim of the study is to compare the quantitative (using 15O-H2O PET) and&#xD;
      semi-quantitative (using perfusion CMR) assessment of coronary reserve to the presence of&#xD;
      coronary artery lesions documented by multidetector CT coronary angiography.&#xD;
&#xD;
      Methods. 30 patients with heart transplantation &gt; 3 yrs will be included in two heart&#xD;
      transplantation centers (Caen and Rouen university hospitals)&#xD;
&#xD;
      Expected results.&#xD;
&#xD;
        -  To demonstrate that quantitative analysis of coronary reserve using 15O-H2O PET allows&#xD;
           the assessment of cardiac allograft vasculopathy&#xD;
&#xD;
        -  To establish the feasibility of adenosine stress CMR in this population&#xD;
&#xD;
        -  To show a relationship between coronary lesions demonstrated using MDCT and the extent&#xD;
           of coronary reserve impairment assessed using cardiac functional imaging (PET and CMR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the coronary flow reserve by a quantitative method (PET ...</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15O-H2O PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>15O-H2O PET -</intervention_name>
    <description>Assessment of coronary reserve using PET</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Assessment of coronary reserve using MRI</description>
    <arm_group_label>MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with heart transplantation &gt; 3 years&#xD;
&#xD;
          -  Candidate to a routine coronary angiography&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding women&#xD;
&#xD;
          -  Recent acute coronary syndrome (&lt;4weeks)&#xD;
&#xD;
          -  High Blood Pressure ((SBP &gt;=180 mmHg or DBP &gt;=110 mmHg)&#xD;
&#xD;
          -  Significant ventricular or supraventricular arrythmia&#xD;
&#xD;
          -  Atrioventricular 2nd or 3rd degree blocks, long QT syndrome&#xD;
&#xD;
          -  Standard contraindications to MRI including pacemaker/defibrillator, metallic clips on&#xD;
             brain aneurysms, metal fragment in the eye etc...&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Intolerance or contraindication to adenosine (history of asthma or bronchoplastic&#xD;
             disease).&#xD;
&#xD;
          -  Severe and known pulmonary artery hypertension&#xD;
&#xD;
          -  Severe hypotension &lt; 90 mmHg&#xD;
&#xD;
          -  Contraindication to contrast iodinated media (allergy, patients with chronic renal&#xD;
             failure with creatinine clearance &lt; 50 ml/min, multiple myeloma, hyperthyroidism,...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Manrique, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIP Cyceron - CHU de Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain MANRIQUE, MD</last_name>
    <phone>+33 2 31 47 02 87</phone>
    <email>manrique@cyceron.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denis AGOSTINI, PhD</last_name>
    <phone>+33 2 31 06 32 46</phone>
    <email>agostini-d@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Caen - GIP Cyceron</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain MANRIQUE, MD</last_name>
      <phone>+33 2 31 47 02 82</phone>
      <email>manrique@cyceron.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia BONDIS</last_name>
      <phone>+33 2 31 06 57 80</phone>
      <email>bondis-c@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Rémi SABATIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette BELIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michèle HAMON, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel REDONNET, MD</last_name>
      <phone>+33 2 32 88 81 97</phone>
      <email>Michel.Redonnet@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Catherine NAFEH, MD</last_name>
      <phone>+33 2 32 88 81 97</phone>
      <email>catherine.nafeh-bizet@chu-rouen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Nicolas DACHER, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

